Peptide-enabled receptor-binding-quantum dots for enhanced detection and migration inhibition of cancer cells

Abstract We report the efforts to construct active targeting quantum dots using receptor-binding peptide for enhanced detection and migration inhibition of cancer cells. Peptide E5 has specific binding with chemokine receptor 4 (CXCR4), which is a transmembrane G-coupled receptor involved in the metastasis of various types of cancers. E5 was introduced to the surface of CdSe/ZnS quantum dots via biotin-streptavidin interactions. The constructed CXCR4-targeting quantum dots (E5@QDs) was observed to display improved detection sensitivity and significantly enhanced binding affinity for CXCR4 over-expressed cancer cells, and the ability to inhibit cancer cells migration induced by CXCL12.

[1]  P. Weiss,et al.  Principles of Inter-Amino-Acid Recognition Revealed by Binding Energies between Homogeneous Oligopeptides , 2019, ACS central science.

[2]  Carolyn M. Beans.  News Feature: Targeting metastasis to halt cancer’s spread , 2018, Proceedings of the National Academy of Sciences.

[3]  Chen Wang,et al.  Improving the inhibitory effect of CXCR4 peptide antagonist in tumor metastasis with an acetylated PAMAM dendrimer , 2018, RSC advances.

[4]  B. Qiu,et al.  Peptide-modified vemurafenib-loaded liposomes for targeted inhibition of melanoma via the skin. , 2018, Biomaterials.

[5]  M. Mohty,et al.  Plerixafor in non-Hodgkin’s lymphoma patients: a German analysis of time, effort and costs , 2018, Bone Marrow Transplantation.

[6]  J. Meng,et al.  Targeting the CXCR4/CXCL12 axis with the peptide antagonist E5 to inhibit breast tumor progression , 2017, Signal Transduction and Targeted Therapy.

[7]  Haiyan Xu,et al.  Anti-tumor activity of nanomicelles encapsulating CXCR4 peptide antagonist E5 , 2017, PloS one.

[8]  Chen Wang,et al.  Allosteric Modulation of Human Serum Albumin Induced by Peptide Ligand , 2017 .

[9]  Chen Wang,et al.  Dual-affinity peptide mediated inter-protein recognition. , 2016, Organic & biomolecular chemistry.

[10]  C. Murray,et al.  NeutrAvidin Functionalization of CdSe/CdS Quantum Nanorods and Quantification of Biotin Binding Sites using Biotin-4-Fluorescein Fluorescence Quenching. , 2016, Bioconjugate chemistry.

[11]  A. Horovitz,et al.  Allosteric Mechanisms in Chaperonin Machines. , 2016, Chemical reviews.

[12]  J. Meng,et al.  Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis , 2015, Scientific Reports.

[13]  I. Nabiev,et al.  Multiphoton imaging of tumor biomarkers with conjugates of single-domain antibodies and quantum dots. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[14]  J. Meng,et al.  A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo , 2014, Scientific Reports.

[15]  Xing-jie Liang,et al.  Functionalized nanoscale micelles improve drug delivery for cancer therapy in vitro and in vivo. , 2013, Nano letters.

[16]  Nikolay V Dokholyan,et al.  Controlling Allosteric Networks in Proteins. , 2013, Chemical reviews.

[17]  L. Lai,et al.  Identifying Allosteric Binding Sites in Proteins with a Two-State Go̅ Model for Novel Allosteric Effector Discovery. , 2012, Journal of chemical theory and computation.

[18]  Jing-Wen Ma,et al.  A totally synthetic, self-assembling, adjuvant-free MUC1 glycopeptide vaccine for cancer therapy. , 2012, Journal of the American Chemical Society.

[19]  R. Vij,et al.  A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. , 2012, Blood.

[20]  Andrew Emili,et al.  Nanoparticle size and surface chemistry determine serum protein adsorption and macrophage uptake. , 2012, Journal of the American Chemical Society.

[21]  Anna Waller,et al.  Simultaneous in vitro molecular screening of protein-peptide interactions by flow cytometry, using six Bcl-2 family proteins as examples , 2011, Nature Protocols.

[22]  M. Bruchez,et al.  Biotin-4-Fluorescein Based Fluorescence Quenching Assay for Determination of Biotin Binding Capacity of Streptavidin Conjugated Quantum Dots , 2011, Bioconjugate chemistry.

[23]  Hong Xu,et al.  Fluorescent, superparamagnetic nanospheres for drug storage, targeting, and imaging: a multifunctional nanocarrier system for cancer diagnosis and treatment. , 2010, ACS nano.

[24]  P. Tinnefeld,et al.  A high sensitive and specific QDs FRET bioprobe for MNase. , 2008, Chemical communications.

[25]  M. Lübbert,et al.  CXCR4 is a prognostic marker in acute myelogenous leukemia. , 2007, Blood.

[26]  P. Steeg.  Tumor metastasis: mechanistic insights and clinical challenges , 2006, Nature Medicine.

[27]  Jason E Gestwicki,et al.  Synthetic multivalent ligands as probes of signal transduction. , 2006, Angewandte Chemie.

[28]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[29]  F. Balkwill.  The significance of cancer cell expression of the chemokine receptor CXCR4. , 2004, Seminars in cancer biology.

[30]  Jonathan S Dordick,et al.  Silica nanoparticle size influences the structure and enzymatic activity of adsorbed lysozyme. , 2004, Langmuir : the ACS journal of surfaces and colloids.

[31]  J. Juarez,et al.  Chemokines and their receptors as therapeutic targets: the role of the SDF-1/CXCR4 axis. , 2004, Current pharmaceutical design.

[32]  A. Carlsson,et al.  Model study of protein unfolding by interfaces. , 2004, Physical review. E, Statistical, nonlinear, and soft matter physics.

[33]  Erkki Ruoslahti,et al.  Nanocrystal targeting in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[34]  L. Bendall,et al.  The chemokine receptor CXCR4 enhances integrin-mediated in vitro adhesion and facilitates engraftment of leukemic precursor-B cells in the bone marrow. , 2001, Experimental hematology.

[35]  T. Wandless,et al.  Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[36]  S. Rafii,et al.  The chemokine receptor CXCR-4 is expressed on CD34+ hematopoietic progenitors and leukemic cells and mediates transendothelial migration induced by stromal cell-derived factor-1. , 1998, Blood.

[37]  S. Law,et al.  Leukemic stromal hematopoietic microenvironment negatively regulates the normal hematopoiesis in mouse model of leukemia. , 2010, Chinese journal of cancer.

[38]  A. Peled,et al.  CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers , 2009, Leukemia.